Die Rheumatologie bewegt sich oft an den Grenzen mit anderen Fachgebieten. Hauterkrankungen bilden eine solche Situation; diese können diagnostisch weiterführen, als Manifestation einer Rheumaerkrankung auftreten oder auch in Folge von Rheumatherapien. Für die Koordination des Schwerpunktes Rheuma und Haut danken wir den Herren Professoren Diego Kyburz und Alexander Navarini vom Universitätsspital Basel. Besonders illustrativ sind die zahlreichen klinischen Abbildungen.
Auch die Rubrik der Kinder- und Jugendrheumatologie widmet sich dem Thema Rheuma und Haut und ergänzt in dieser Weise den Schwerpunkt.

Wir hoffen, mit dieser Ausgabe Ihr Interesse zu finden.

Viel Vergnügen bei der Lektüre,
Für die Redaktion
Prof. Dr. med. Beat Michel, Zürich

Ausgabe Herunterladen

Literaturhinweise

Differentialdiagnosen Psoriasis und Psoriasis Arthritis

Seite 17:

Referenzen

  1. Parisi, Rosa et al. “National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study.” BMJ (Clinical research ed.) vol. 369 m1590. 28 May. 2020, doi:10.1136/bmj.m1590
  2. Michalek, I M et al. “A systematic review of worldwide epidemiology of psoriasis.” Journal of the European Academy of Dermatology and Venereology: JEADV vol. 31,2 (2017): 205–212. doi:10.1111/jdv.13854
  3. Langley, R G B et al. “Psoriasis: epidemiology, clinical features, and quality of life.” Annals of the rheumatic diseases vol. 64 Suppl 2,Suppl 2 (2005): ii18–23; discussion ii24–5. doi:10.1136/ard.2004.033217
  4. Napolitano M, Caso F, Scarpa R, Megna M, Patrì A, Balato N, Costa L. Psoriatic arthritis and psoriasis: differential dia- gnosis. Clin Rheumatol. 2016 Aug;35(8):1893–1901. doi: 10.1007/s10067-016-3295-9. Epub 2016 May 7. PMID: 27156076
  5. Gerdes, S et al. „Differenzialdiagnostisches Spektrum der Psoriasis versus Psoriasisarthritis an Haut und Gelenken” [Differential diagnostic spectrum of psoriasis vs. psoriatic arthritis in skin and joints]. Zeitschrift fur Rheumatologie vol. 76,6 (2017): 484-494. doi:10.1007/s00393-017-0340-2
  6. Wagner, G., V. Meyer, and M.M. Sachse. „Verruköse Variante der Porokeratosis Mibelli als Differenzialdiagnose der Psoriasis vulgaris.“ Der Hautarzt 67.3 (2015): 244-248
  7. Omland, Silje Haukali, and Robert Gniadecki. “Psoriasis inversa: A separate identity or a variant of psoriasis vulgaris?.” Clinics in dermatology vol. 33,4 (2015): 456-61. doi:10.1016/j.clindermatol.2015.04.007
  8. Pfohler, Claudia et al. “Psoriasis vulgaris and psoriasis pustulosa - epidemiology, quality of life, comorbidities and tre- atment.” Current rheumatology reviews vol. 9,1 (2013): 2–7. doi:10.2174/1573397111309010002
  9. Manhart, Racheal, and Phoebe Rich. “Nail psoriasis.” Clinical and experimental rheumatology vol. 33,5 Suppl 93 (2015): S7–13
  10. Guglielmo, Alba et al. “Erythroderma: psoriasis or lymphoma? A diagnostic challenge and therapeutic pitfall.” Italian journal of dermatology and venereology vol 157,2 (2022): 154–157. doi:10.23736/S2784-8671.21.06891-7
  11. Olivieri, Ignazio et al. “Psoriatic arthritis sine psoriasis.” The Journal of rheumatology. Supplement vol. 83 (2009): 28–9. doi:10.3899/jrheum.090218
  12. Moll, J M, and V Wright. “Psoriatic arthritis.” Seminars in arthritis and rheumatism vol. 3,1 (1973): 55–78. doi:10.1016/0049-0172(73)90035-8
  13. Coates, Laura C, and Philip S Helliwell. “Psoriatic arthritis: state of the art review.” Clinical medicine (London, Eng- land) vol. 17,1 (2017): 65–70. doi:10.7861/clinmedicine. 17-1-65
  14. Lorenz, H. “Kollagenosen” [Connective tissue diseases]. Deutsche medizinische Wochenschrift (1946) vol. 139,14 (2014): 711–3. doi:10.1055/s-0034-1369824
  15. Bekou, V., G. Bonsmann, and A. Kuhn. „Kollagenosen.“ Monatsschrift Kinderheilkunde 156.2 (2008): 122–131
  16. Plewig, G., Ruzicka, T., Kaufmann R., Herta M., (Hrsg.) Braun-Falcos Dermatologie, Venerologie und Allergologie. (2018) Springer Medizin Verlag
  17. Wissenswertes rund um die Diagnostik. Kompass Dermatol 2018;6:218–223. doi: 10.1159/000492773

Formen des kutanen Lupus

Seite 32:

Referenzen

  1. Felten R, Lipsker D, Sibilia J, Chasset F, Arnaud L. The history of lupus throughout the ages. J Am Acad Dermatol. Dec 2022;87(6):1361–1369. doi:10.1016/j.jaad.2020.04.150
  2. Smith CD, Cyr M. The history of lupus erythematosus. From Hippocrates to Osler. Rheum Dis Clin North Am. Apr 1988;14(1):1–14
  3. Mallavarapu RK, Grimsley EW. The history of lupus erythematosus. South Med J. Sep 2007;100(9):896–8. doi:10.1097/SMJ.0b013e318073c9eb
  4. David-Bajar KM. Subacute cutaneous lupus erythematosus. J Invest Dermatol. Jan 1993;100(1):2S–8S. doi:10.1111/1523-1747.ep12355164
  5. Walling HW, Sontheimer RD. Cutaneous lupus erythematosus: issues in diagnosis and treatment. Am J Clin Dermatol. 2009;10(6):365–81. doi:10.2165/11310780-000000000-00000
  6. Petri M. Epidemiology of systemic lupus erythematosus. Best Pract Res Clin Rheumatol. Dec 2002;16(5):847-58. doi:10.1053/berh.2002.0259
  7. Parks CG, de Souza Espindola Santos A, Barbhaiya M, Costenbader KH. Understanding the role of environmental factors in the development of systemic lupus erythematosus. Best Pract Res Clin Rheumatol. Jun 2017;31(3):306–320. doi:10.1016/j.berh.2017.09.005
  8. Moser KL, Kelly JA, ­Lessard CJ, Harley JB. Recent insights into the genetic basis of systemic lupus erythematosus. Genes Immun. Jul 2009;10(5):373–9. doi:10.1038/gene.2009.39
  9. Järvinen TM, Hellquist A, Koskenmies S, et al. Tyrosine kinase 2 and interferon regulatory factor 5 polymorphisms are associated with discoid and subacute cutaneous lupus erythematosus. Exp Dermatol. Feb 2010;19(2):123–31. doi:10.1111/j.1600-0625.2009.00982.x
  10. Derdulska JM, Rudnicka L, Szykut-Badaczewska A, et al. Neonatal lupus erythematosus – practical guidelines. J Perinat Med. Jun 25 2021;49(5):529–538. doi:10.1515/jpm-2020-0543
  11. Filotico R, Mastrandrea V. Cutaneous lupus erythematosus: clinico-pathologic correlation. G Ital Dermatol Venereol. Apr 2018;153(2):216-229. doi:10.23736/S0392-0488.18.05929-1
  12. StatPearls. 2022
  13. Jarrett P, Werth VP. A review of cutaneous lupus erythematosus: improving outcomes with a multidisciplinary approach. J Multidiscip Healthc. 2019;12:419–428. doi:10.2147/JMDH.S179623
  14. He Y, Sawalha AH. Drug-induced lupus erythematosus: an update on drugs and mechanisms. Curr Opin Rheumatol. Sep 2018;30(5):490–497. doi:10.1097/BOR.0000000000000522
  15. Callen JP. Drug-induced subacute cutaneous lupus erythematosus. Lupus. Aug 2010;19(9):1107-11. doi:10.1177/0961203310370349
  16. Lenormand C, Lipsker D. Lupus erythematosus: Significance of dermatologic findings. Ann Dermatol Venereol. Mar 2021;148(1):6–15. doi:10.1016/j.annder.2020.08.052
  17. Pona A, Cardenas-de la Garza JA, Broderick A, et al. Lupus Erythematosus Tumidus Clinical Characteristics and Treatment: A Retrospective Review of 25 Patients. Cutis. Jun 2022;109(6):330–332. doi:10.12788/cutis.0544
  18. Rangel LK, Villa-Ruiz C, Lo K, et al. Clinical Characteristics of Lupus Erythematosus Panniculitis/Profundus: A Retrospective Review of 61 Patients. JAMA Dermatol. Nov 01 2020;156(11):1264-1266. doi:10.1001/jamadermatol.2020.2797
  19. Su WP, Perniciaro C, Rogers RS, White JW. Chilblain lupus erythematosus (lupus pernio): clinical review of the Mayo Clinic experience and proposal of diagnostic criteria. Cutis. Dec 1994;54(6):395–9
  20. Hon KL, Leung AK. Neonatal lupus erythematosus. Autoimmune Dis. 2012;2012:301274. doi:10.1155/2012/301274
  21. Baltaci M, Fritsch P. Histologic features of cutaneous lupus erythematosus. Autoimmun Rev. May 2009;8(6):467–73. doi:10.1016/j.autrev.2008.12.014
  22. Hood AF, Farmer ER. Histopathology of cutaneous lupus erythematosus. Clin Dermatol. 1985;3(3):36–48. doi:10.1016/0738-081x(85)90076-8
  23. Sugai SA, Gerbase AB, Cernea SS, et al. Cutaneous lupus erythematosus: direct immunofluorescence and epidermal basal membrane study. Int J Dermatol. Apr 1992;31(4):260–4. doi:10.1111/j.1365-4362.1992.tb03567.x
  24. Bharti S, Dogra S, Saikia B, Walker RM, Chhabra S, Saikia UN. Immunofluorescence profile of discoid lupus erythematosus. Indian J Pathol Microbiol. 2015;58(4):479–82. doi:10.4103/0377-4929.168850
  25. Okon LG, Werth VP. Cutaneous lupus erythematosus: diagnosis and treatment. Best Pract Res Clin Rheumatol. Jun 2013;27(3):391–404. doi:10.1016/j.berh.2013.07.008
  26. Grygiel-Górniak B, Rogacka N, Puszczewicz M. Antinuclear antibodies in healthy people and non-rheumatic diseases – diagnostic and clinical implications. Reumatologia. 2018;56(4):243–248. doi:10.5114/reum.2018.77976
  27. Lu Q, Long H, Chow S, et al. Guideline for the diagnosis, treatment and long-term management of cutaneous lupus erythematosus. J Autoimmun. Sep 2021;123:102707. doi:10.1016/j.jaut.2021.102707

Derma-Rheuma – Fallbeispiele aus der interdisziplinären, pädiatrischen Sprechstunde

Seite 52:

Referenzen

  1. Koryllou A, Mejbri M, Theodoropoulou K, Hofer M, Carlomagno R. Chronic nonbacterial osteomyelitis in children. Children. 2021 Jul 1;8(7)
  2. Cyrenne BM, Parpia AS, Sibbald C. Paradoxical psoriasis in pediatric patients: A systematic review. Pediatr Dermatol. 2021;(June):1086–93
  3. Conrad C, di Domizio J, Mylonas A, Belkhodja C, Demaria O, Navarini AA, et al. TNF blockade induces a dysregulated type i interferon response without autoimmunity in paradoxical psoriasis. Nat Commun. 2018 Dec 1;9(1)
  4. Brown G, Wang E, Leon A, Huynh M, Wehner M, Matro R, et al. Tumor necrosis factor-α inhibitor-induced psoriasis: Systematic review of clinical features, histopathological findings, and management experience. Vol. 76, Journal of the American Academy of Dermatology. Mosby Inc.; 2017. p. 334–41
  5. Bataille P, Layese R, Claudepierre P, Paris N, Dubiel J, Amiot A, et al. Paradoxical reactions and biologic agents: a French cohort study of 9303 patients*. British Journal of Dermatology. 2022 Nov 1;187(5):676–83
  6. Kodama S, Gupta D, Sullivan E, Rosenwasser N, Zhao Y. Paradoxical psoriasis after exposure to tumour necrosis factor inhibitors in children: a retrospective cohort study. Vol. 186, British Journal of Dermatology. John Wiley and Sons Inc; 2022. p. 1043–5
  7. Campbell JA, Kodama SS, Gupta D, Zhao Y. Case series of psoriasis associated with tumor necrosis factor-α inhibitors in children with chronic recurrent multifocal osteomyelitis. JAAD Case Rep. 2018 Sep 1;4(8):767–71
  8. Rosenwasser N, Lee D, Sidbury R, Zhao Y. Paradoxical Psoriasis in Children Receiving Anti-TNFα Treatment for Inflammatory/autoimmune Disease. Vol. 23, Pediatric Drugs. Adis; 2021. p. 131–41
  9. Buckley LH, Xiao R, Perman MJ, Grossman AB, Weiss PF. Psoriasis Associated With Tumor Necrosis Factor Inhibitors in Children With Inflammatory Diseases. Arthritis Care Res (Hoboken). 2021 Feb 1;73(2):215–20
  10. Karaosmanoğlu N, Mülkoğlu C. Analysis of musculoskeletal side effects of oral Isotretinoin treatment: A cross-sectional study. BMC Musculoskelet Disord. 2020;21(1):1–10
  11. Baykal Selçuk L, Aksu Arıca D, Baykal Şahin H, Yaylı S, Bahadır S. The prevalence of sacroiliitis in patients with acne vulgaris using isotretinoin. Cutan Ocul Toxicol. 2017;36(2):176–9
  12. Elnady B, Elkhouly T, Dawoud NM, Desouky DE, Kewan HH, Dawoud DM, et al. New onset of axial spondyloarthropathy in patients treated with isotretinoin for acne vulgaris: incidence, follow-up, and MRI findings. Clin Rheumatol. 2020
  13. Alkan S, Kayiran N, Zengin O, Kalem A, Kimyon G, Kilinc EO, et al. Isotretinoin-induced spondyloarthropathy-related symptoms: A prospective study. Journal of Rheumatology. 2015;42(11):2106–9
  14. Yilmaz Tasdelen O, Yurdakul FG, Duran S, Bodur H. Isotretinoin-induced arthritis mimicking both rheumatoid arthritis and axial spondyloarthritis. Int J Rheum Dis. 2015;18(4):466–9
  15. Karadağ ŞG, Sönmez HE, Tanatar A, Çakan M, Aktay Ayaz N. Isotretinoin-induced sacroiliitis: Case series of four patients and a systematic review of the literature. Pediatr Dermatol. 2020;37(1):171–5
  16. Zulian F, Vallongo C, Woo P, Russo R, Ruperto N, Harper J, et al. Localized scleroderma in childhood is not just a skin disease. Arthritis Rheum. 2005 Sep;52(9):2873–81
  17. Constantin T, Foeldvari I, Pain CE, Pálinkás A, Höger P, Moll M, et al. Development of minimum standards of care for juvenile localized scleroderma. Vol. 177, European Journal of Pediatrics. Springer Verlag; 2018. p. 961–77
  18. Li SC, Torok KS, Ishaq SS, Buckley M, Edelheit B, Ede KC, et al. Preliminary evidence on abatacept safety and efficacy in refractory juvenile localized scleroderma. Rheumatology (Oxford). 2021 Aug 2;60(8):3817–25
  19. Weibel L. Diagnosis and management of morphoea in children: an overview. Vol. 46, Clinical and Experimental Dermatology. Blackwell Publishing Ltd; 2021. p. 487–94
  20. Foeldvari I, Culpo R, Sperotto F, Anton J, Avcin T, Baildam E, et al. Consensus-based recommendations for the management of juvenile systemic sclerosis. Rheumatology (United Kingdom). 2021 Apr 1;60(4):1651–8
  21. Torok KS, Li SC, Jacobe HM, Taber SF, Stevens AM, Zulian F, et al. Immunopathogenesis of pediatric localized scleroderma. Vol. 10, Frontiers in Immunology. Frontiers Media S.A.; 2019
  22. Herrick AL, Ennis H, Bhushan M, Silman AJ, Baildam EM. Incidence of childhood linear scleroderma and systemic sclerosis in the UK and Ireland. Arthritis Care Res (Hoboken). 2010;62(2):213–8
  23. Weibel L, Laguda B, Atherton D, Harper JI. Misdiagnosis and delay in referral of children with localized scleroderma. Vol. 165, British Journal of Dermatology. Blackwell Publishing Ltd; 2011. p. 1308–13
  24. Martini G, Fadanelli G, Agazzi A, Vittadello F, Meneghel A, Zulian F. Disease course and long-term outcome of juvenile localized scleroderma: Experience from a single pediatric rheumatology Centre and literature review. Vol. 17, Autoimmunity Reviews. Elsevier B.V.; 2018. p. 727–34
  25. Lis-Święty A, Janicka I, Skrzypek-Salamon A, Brzezińska-Wcisło L. A systematic review of tools for determining activity of localized scleroderma in paediatric and adult patients. Vol. 31, Journal of the European Academy of Dermatology and Venereology. Blackwell Publishing Ltd; 2017. p. 30–7
  26. Peterson L, Nelson A, Su W. Classification of morphea (localized scleroderma). May Clinic proceedings. 1995;70(11):1068–76
  27. Zulian F, Culpo R, Sperotto F, Anton J, Avcin T, Baildam EM, et al. Consensus-based recommendations for the management of juvenile localised scleroderma. Ann Rheum Dis. 2019 Mar 2;annrheumdis-2018-214697
  28. Zulian F, Athreya BH, Laxer R, Nelson AM, Feitosa de Oliveira SK, Punaro MG, et al. Juvenile localized scleroderma: Clinical and epidemiological features in 750 children. An international study. Rheumatology. 2006 May;45(5):614–20
  29. Weibel L, Theiler M, Howell KJ, Denton CP, Waelchli R, Atherton D, et al. Prospective evaluation of treatment response and disease reversibility of paediatric localized scleroderma (morphoea) to steroids and methotrexate using multi-modal imaging. Journal of the European Academy of Dermatology and Venereology. 2020;34(7):1609–16.
  30. Li SC, Torok KS, Pope E, Dedeoglu F, Hong S, Jacobe HT, et al. Development of consensus treatment plans for juvenile localized scleroderma: A roadmap toward comparative effectiveness studies in juvenile localized scleroderma. Arthritis Care Res (Hoboken). 2012 Aug;64(8):1175–85
  31. Weibel L, Sampaio MC, Visentin MT, Howell KJ, Woo P, Harper JI. Evaluation of methotrexate and corticosteroids for the treatment of localized scleroderma (morphoea) in children. British Journal of Dermatology. 2006 Nov;155(5):1013–20
  32. Martini G, Ramanan A v., Falcini F, Girschick H, Goldsmith DP, Zulian F. Successful treatment of severe or methotrexate-resistant juvenile localized scleroderma with mycophenolate mofetil. Rheumatology (Oxford). 2009;48(11):1410–3
  33. Arthur M, Fett NM, Latour E, Jacobe H, Kunzler E, Florez-Pollack S, et al. Evaluation of the Effectiveness and Tolerability of Mycophenolate Mofetil and Mycophenolic Acid for the Treatment of Morphea. JAMA Dermatol. 2020;156(5):521–8
  34. Martini G, Saggioro L, Culpo R, Vittadello F, Meneghel A, Zulian F. Mycophenolate mofetil for methotrexate-resistant juvenile localized scleroderma. Rheumatology (United Kingdom). 2021 Mar 1;60(3):1387–91
  35. Wehner Fage S, Arvesen KB, Olesen AB. Abatacept improves skin-score and reduces lesions in patients with localized scleroderma: A case series. Vol. 98, Acta Dermato-Venereologica. Medical Journals/Acta D-V; 2018. p. 465–6
  36. Mertens JS, Seyger MMB, Kievit W, Hoppenreijs EPAH, Jansen TLTA, van de Kerkhof PCM, et al. Disease recurrence in localized scleroderma: A retrospective analysis of 344 patients with paediatric- or adult-onset disease. British Journal of Dermatology. 2015 Mar 1;172(3):722–8